Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,104 matching trials from the live ClinicalTrials.gov search.
Filters: "metformin" Clear all
Completed Phase 1 Interventional

Study of Erlotinib and Metformin in Triple Negative Breast Cancer

NCT01650506
View directory record Official record
Conditions
Breast Cancer
Interventions
Metformin, Erlotinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

A Safety Study of ARRY-403 in Patients With Type 2 Diabetes

NCT00952198
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ARRY-403, glucokinase activator; oral, Placebo; oral
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

NCT01451398
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Technosphere® Insulin, Technosphere Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
50
States / cities
Anaheim, California • Huntington Beach, California • Laguna Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2014 · Synced Oct 11, 2026, 5:11 AM EDT
Active, not recruiting Not applicable Interventional

Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)

NCT05040087
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Intensification of diabetes medication based largely on HbA1c levels, Intensification of diabetes medication based on glucose levels
Other
Lead sponsor
Foundation for Atlanta Veterans Education and Research, Inc.
Other
Eligibility
40 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 3 Interventional

Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy

NCT00598793
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, insulin glargine, metformin, pioglitazone
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
27
States / cities
Concord, California • Los Angeles, California • Walnut Creek, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 4 Interventional Results available

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

NCT02730377
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, alpha-glucosidase inhibitors, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylurea, thiazolidinediones
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
179
States / cities
Birmingham, Alabama • Haleyville, Alabama • Tuscumbia, Alabama + 157 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients

NCT02435277
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Low Metformin, Mid Metformin, High Metformin, Metformin
Drug
Lead sponsor
NuSirt Biopharma
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Chino, California • Palm Beach, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 4 Interventional

Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)

NCT04979130
View directory record Official record
Conditions
Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 11, 2026, 5:11 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Study of a Diabetes Prevention Patient Activation Clinical Decision Support Tool

NCT06358261
View directory record Official record
Conditions
PreDiabetes, Lifestyle, Healthy, Activation, Patient
Interventions
Diabetes Prevention Patient Activation Clinical Decision Support Tool
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 4 Interventional

An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.

NCT00391261
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Autism Spectrum Disorders
Interventions
Metformin
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
10 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2010 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 2 Interventional

Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction

NCT05093959
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Metformin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

NCT00753896
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
11
States / cities
Mesa, Arizona • Tempe, Arizona • Concord, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Oct 11, 2026, 5:11 AM EDT
Terminated Not applicable Interventional Results available

Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia

NCT00794963
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan, As selected by community physician
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
19 Years to 79 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 11, 2026, 5:11 AM EDT
Active, not recruiting Phase 1 Interventional

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

NCT02336087
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Unresectable Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, Therapeutic Dietary Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Drug · Dietary Supplement · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
4
States / cities
Duarte, California • Rancho Cucamonga, California • South Pasadena, California + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

NCT01664247
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, placebo, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
67
States / cities
Anaheim, California • Concord, California • Escondido, California + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

NCT00996658
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 79 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
29
States / cities
Escondido, California • Greenbrae, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans

NCT01681693
View directory record Official record
Conditions
Healthy, Type 2 Diabetes Mellitus
Interventions
Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 4 Interventional Results available

Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy

NCT01859793
View directory record Official record
Conditions
Diabetes, Atherosclerosis
Interventions
sitagliptin, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)

NCT01106625
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin, Placebo, Metformin, Sulphonylruea
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
Huntsville, Alabama • Little Rock, Alaska • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02865668
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 11, 2026, 5:11 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Endometrial Cancer Recurrence in Patients Taking Metformin

NCT05192850
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma
Interventions
Metformin use
Drug
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years to 99 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction With Metformin

NCT00546741
View directory record Official record
Conditions
Healthy Male and Female Subjects
Interventions
Dapagliflozin, Metformin, Dapagliflozin + Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

NCT00789750
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Colesevelam, Placebo, Pioglitazone
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
141
States / cities
Birmingham, Alabama • Montgomery, Alabama • Green Valley, Arizona + 114 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 11, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

NCT02926950
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Placebo, Metformin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Canoga Park, California + 50 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 11, 2026, 5:11 AM EDT